



# SAFETY DATA SHEET

Revision date: 16-Jun-2014

Version: 4.1

Page 1 of 10

## 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

### Product Identifier

**Material Name:** Doxazosin mesylate tablets

**Trade Name:** CARDURA, ALFADIL, BENUR, CARDENALIN, CARDORAL, CARDULAR, CARDURAN, DAXIREN, DOXABEN, PROSTADILAT, SUPRESSIN

**Chemical Family:** Quinazoline derivative

### Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

**Intended Use:** Pharmaceutical product used for high blood pressure (hypertension); benign prostatic hyperplasia

### Details of the Supplier of the Safety Data Sheet

Pfizer Inc  
Pfizer Pharmaceuticals Group  
235 East 42nd Street  
New York, New York 10017  
1-800-879-3477

Pfizer Ltd  
Ramsgate Road  
Sandwich, Kent  
CT13 9NJ  
United Kingdom  
+00 44 (0)1304 616161

Emergency telephone number:  
CHEMTREC (24 hours): 1-800-424-9300  
Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:  
International CHEMTREC (24 hours): +1-703-527-3887

## 2. HAZARDS IDENTIFICATION

### Classification of the Substance or Mixture

**GHS - Classification** Not classified as hazardous

### EU Classification:

EU Indication of danger: Not classified

### Label Elements

### Other Hazards

No data available

### Australian Hazard Classification (NOHSC):

Non-Hazardous Substance. Non-Dangerous Goods.

### Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### Additional Information:

For a more detailed discussion of potential health hazards and toxicity see Section 11.

## 3. COMPOSITION / INFORMATION ON INGREDIENTS

### Hazardous

## SAFETY DATA SHEET

Material Name: Doxazosin mesylate tablets  
Revision date: 16-Jun-2014

Page 2 of 10  
Version: 4.1

### 3. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Doxazosin mesylate	77883-43-3	Not Listed	Xn;R48/22	STOT RE 2 (H373) Aquatic Acute 2 (H401) Aquatic Chronic 2 (H411)	1.0 - 4.0
Magnesium Stearate	557-04-0	209-150-3	Not Listed	Not Listed	*
Microcrystalline cellulose	9004-34-6	232-674-9	Not Listed	Not Listed	*
Sodium Lauryl Sulfate	151-21-3	205-788-1	Not Listed	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
D & C yellow No. 10	8004-92-0	Not Listed	Not Listed	Not Listed	*
FD&C Blue No. 2	860-22-0	212-728-8	Not Listed	Not Listed	*
FD&C yellow No.6 aluminum lake	15790-07-5	239-888-1	Not Listed	Not Listed	*
Lactose NF, anhydrous	63-42-3	200-559-2	Not Listed	Not Listed	*
Sodium starch glycolate	9063-38-1	Not Listed	Not Listed	Not Listed	*

**Additional Information:**

\* Proprietary  
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.  
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases mentioned in this Section, see Section 16

### 4. FIRST AID MEASURES

**Description of First Aid Measures**

<b>Eye Contact:</b>	Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.
<b>Skin Contact:</b>	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
<b>Ingestion:</b>	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
<b>Inhalation:</b>	Remove to fresh air and keep patient at rest. Seek medical attention immediately.

**Most Important Symptoms and Effects, Both Acute and Delayed**

<b>Symptoms and Effects of Exposure:</b>	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
<b>Medical Conditions Aggravated by Exposure:</b>	None known

**Indication of the Immediate Medical Attention and Special Treatment Needed**

<b>Notes to Physician:</b>	None
----------------------------	------

## SAFETY DATA SHEET

Material Name: Doxazosin mesylate tablets  
Revision date: 16-Jun-2014

Page 3 of 10  
Version: 4.1

### 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Use carbon dioxide, dry chemical, or water spray.

**Special Hazards Arising from the Substance or Mixture**

**Hazardous Combustion Products:** Formation of toxic gases is possible during heating or fire.

**Fire / Explosion Hazards:** Not determined

**Advice for Fire-Fighters**

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

### 6. ACCIDENTAL RELEASE MEASURES

**Personal Precautions, Protective Equipment and Emergency Procedures**

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

**Environmental Precautions**

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

**Methods and Material for Containment and Cleaning Up**

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

**Additional Consideration for Large Spills:** Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

### 7. HANDLING AND STORAGE

**Precautions for Safe Handling**

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

**Conditions for Safe Storage, Including any Incompatibilities**

**Storage Conditions:** Store as directed by product packaging.

**Specific end use(s):** Pharmaceutical drug product

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

**Control Parameters**

Refer to available public information for specific member state Occupational Exposure Limits.

**Doxazosin mesylate**

Pfizer OEL TWA-8 Hr: 30µg/m<sup>3</sup>

**Magnesium Stearate**

ACGIH Threshold Limit Value (TWA) 10 mg/m<sup>3</sup>

Lithuania OEL - TWA 5 mg/m<sup>3</sup>

Sweden OEL - TWAs 5 mg/m<sup>3</sup>

## SAFETY DATA SHEET

Material Name: Doxazosin mesylate tablets  
Revision date: 16-Jun-2014

Page 4 of 10  
Version: 4.1

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

#### Microcrystalline cellulose

ACGIH Threshold Limit Value (TWA)	10 mg/m <sup>3</sup>
Australia TWA	10 mg/m <sup>3</sup>
Belgium OEL - TWA	10 mg/m <sup>3</sup>
Estonia OEL - TWA	10 mg/m <sup>3</sup>
France OEL - TWA	10 mg/m <sup>3</sup>
Ireland OEL - TWAs	10 mg/m <sup>3</sup>
	4 mg/m <sup>3</sup>
Latvia OEL - TWA	2 mg/m <sup>3</sup>
OSHA - Final PELs - TWAs:	15 mg/m <sup>3</sup>
Portugal OEL - TWA	10 mg/m <sup>3</sup>
Romania OEL - TWA	10 mg/m <sup>3</sup>
Russia OEL - TWA	6 mg/m <sup>3</sup>
Spain OEL - TWA	10 mg/m <sup>3</sup>
Switzerland OEL - TWAs	3 mg/m <sup>3</sup>
Vietnam OEL - TWAs	10 mg/m <sup>3</sup>
	5 mg/m <sup>3</sup>

#### Exposure Controls

##### Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

##### Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

##### Hands:

Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

##### Eyes:

Wear safety glasses or goggles if eye contact is possible.

##### Skin:

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

##### Respiratory protection:

If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Tablet	Color:	White, yellow, orange, or green
Odor:	Odorless	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture
Solvent Solubility:	No data available		
Water Solubility:	No data available		
pH:	No data available.		
Melting/Freezing Point (°C):	No data available		
Boiling Point (°C):	No data available.		
Partition Coefficient: (Method, pH, Endpoint, Value)			
FD&C yellow No.6 aluminum lake			
No data available			
Sodium starch glycolate			
No data available			
Lactose NF, anhydrous			

## SAFETY DATA SHEET

Material Name: Doxazosin mesylate tablets  
Revision date: 16-Jun-2014

Page 5 of 10  
Version: 4.1

### 9. PHYSICAL AND CHEMICAL PROPERTIES

No data available

**Microcrystalline cellulose**

No data available

**Doxazosin mesylate**

Measured Log P 1.02

**Magnesium Stearate**

No data available

**Sodium Lauryl Sulfate**

No data available

**D & C yellow No. 10**

No data available

**FD&C Blue No. 2**

No data available

**Decomposition Temperature (°C):** No data available.

**Evaporation Rate (Gram/s):** No data available

**Vapor Pressure (kPa):** No data available

**Vapor Density (g/ml):** No data available

**Relative Density:** No data available

**Viscosity:** No data available

**Flammability:**

**Autoignition Temperature (Solid) (°C):** No data available

**Flammability (Solids):** No data available

**Flash Point (Liquid) (°C):** No data available

**Upper Explosive Limits (Liquid) (% by Vol.):** No data available

**Lower Explosive Limits (Liquid) (% by Vol.):** No data available

**Polymerization:** Will not occur

### 10. STABILITY AND REACTIVITY

**Reactivity:** No data available

**Chemical Stability:** Stable under normal conditions of use.

**Possibility of Hazardous Reactions**

**Oxidizing Properties:** No data available

**Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions.

**Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

**Hazardous Decomposition Products:** No data available

### 11. TOXICOLOGICAL INFORMATION

**Information on Toxicological Effects**

**General Information:** The information included in this section describes the potential hazards of the individual ingredients.

**Short Term:** Antihypertensive drug: has blood pressure-lowering properties

**Long Term:** Repeat-dose studies in animals have shown a potential to cause adverse effects on : heart.

**Known Clinical Effects:** Ingestion of this material may cause effects similar to those seen in clinical use including dizziness, fatigue, hypotension (low blood pressure), edema and dyspnea.

**Acute Toxicity: (Species, Route, End Point, Dose)**

## SAFETY DATA SHEET

Material Name: Doxazosin mesylate tablets  
Revision date: 16-Jun-2014

Page 6 of 10  
Version: 4.1

### 11. TOXICOLOGICAL INFORMATION

#### Microcrystalline cellulose

Rat Oral LD50 > 5000 mg/kg  
Rabbit Dermal LD50 > 2000 mg/kg

#### Doxazosin mesylate

Mouse Oral LD50 > 1000 mg/kg  
Rat Oral LD50 > 1200mg/kg  
Mouse (M/F) IV LD50 9/14mg/kg  
Rat (M/F) IV LD50 28/33mg/kg

#### Sodium Lauryl Sulfate

Rat Oral LD 50 1288 mg/kg  
Rat Sub-tenon injection (eye) LD 50 210mg/kg

#### D & C yellow No. 10

Rat Oral LD50 2000 mg/kg

#### FD&C Blue No. 2

Rat Oral LD50 2 g/kg  
Mouse Oral LD50 2500mg/kg

#### Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

#### Irritation / Sensitization: (Study Type, Species, Severity)

##### Microcrystalline cellulose

Skin Irritation Rabbit Non-irritating  
Eye Irritation Rabbit Non-irritating

#### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

##### Doxazosin mesylate

12 Month(s)	Rat	Oral	10 mg/kg/day	NOAEL	Heart, Male reproductive system
12 Month(s)	Dog	Oral	20 mg/kg/day	NOAEL	Heart
3 Month(s)	Dog	Oral	16 mg/kg/day	NOAEL	No effects at maximum dose
6 Month(s)	Rat	Oral	20 mg/kg/day	NOAEL	Heart, Blood

##### Magnesium Stearate

13 Week(s) Rat Oral 1092 g/kg LOAEL Liver

##### Sodium Lauryl Sulfate

3 Day(s) Rat Oral 75 mg/kg LOAEL Liver, Blood

#### Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

##### Doxazosin mesylate

Reproductive & Fertility-Males	Rat	Oral	20 mg/kg/day	LOAEL	Fertility
Fertility and Embryonic Development	Rat	Oral	5 mg/kg/day	NOAEL	Fertility, Not Teratogenic
Embryo / Fetal Development	Rabbit	Oral	40 mg/kg/day	NOAEL	Not Teratogenic
Peri-/Postnatal Development	Rat	Oral	2.5 mg/kg/day	LOAEL	Maternal Toxicity, Developmental toxicity

## SAFETY DATA SHEET

Material Name: Doxazosin mesylate tablets  
Revision date: 16-Jun-2014

Page 7 of 10  
Version: 4.1

### 11. TOXICOLOGICAL INFORMATION

#### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

##### **Doxazosin mesylate**

Bacterial Mutagenicity (Ames)	<i>Salmonella</i>	Negative
<i>In Vitro</i> Cytogenetics	Human Lymphocytes	Negative
<i>In Vivo</i> Cytogenetics	Mouse Bone Marrow	Negative

##### **FD&C Blue No. 2**

Bacterial Mutagenicity (Ames)	<i>Salmonella</i>	Negative
-------------------------------	-------------------	----------

#### Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

##### **Doxazosin mesylate**

18 Month(s)	Mouse	Oral, in feed	10 mg/kg/day	NOAEL	Not carcinogenic, Heart, Kidneys
24 Month(s)	Rat	Oral, in feed	10 mg/kg/day	NOAEL	Not carcinogenic, Reproductive System, Heart

**Carcinogen Status:** None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

### 12. ECOLOGICAL INFORMATION

**Environmental Overview:** In the environment, the active ingredient in this formulation is expected to remain in water or migrate through the soil to groundwater. Harmful effects to aquatic organisms could occur.

#### **Toxicity:**

#### Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

##### **Doxazosin mesylate**

<i>Daphnia magna</i> (Water Flea)	NPDES	LC50	48 Hours	> 5 mg/L
<i>Mysidopsis bahia</i> (Mysid Shrimp)	NPDES	LC50	48 Hours	3.8 mg/L
<i>Pimephales promelas</i> (Fathead Minnow)	NPDES	LC50	48 Hours	> 5 mg/L
<i>Cyprinodon variegatus</i> (Sheepshead Minnow)	NPDES	LC50	48 Hours	> 5 mg/L

**Aquatic Toxicity Comments:** A greater than (>) symbol indicates that acute ecotoxicity was not observed at the maximum solubility. Since the substance is insoluble in aqueous solutions above this concentration, an acute ecotoxicity value (i.e. LC/EC50) is not achievable.

**Persistence and Degradability:** No data available

**Bio-accumulative Potential:** No data available

##### **Doxazosin mesylate**

Measured Log P 1.02

**Mobility in Soil:** No data available

## SAFETY DATA SHEET

Material Name: Doxazosin mesylate tablets  
Revision date: 16-Jun-2014

Page 8 of 10  
Version: 4.1

### 13. DISPOSAL CONSIDERATIONS

**Waste Treatment Methods:** Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

### 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

### 15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

#### Canada - WHMIS: Classifications

##### WHMIS hazard class:

Class D, Division 2, Subdivision A

#### **D & C yellow No. 10**

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

#### **Doxazosin mesylate**

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

#### **FD&C Blue No. 2**

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	212-728-8

#### **FD&C yellow No.6 aluminum lake**

CERCLA/SARA 313 Emission reporting	Not Listed
------------------------------------	------------



## SAFETY DATA SHEET

Material Name: Doxazosin mesylate tablets  
Revision date: 16-Jun-2014

Page 9 of 10  
Version: 4.1

### 15. REGULATORY INFORMATION

California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	239-888-1
<b>Lactose NF, anhydrous</b>	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	200-559-2
<b>Magnesium Stearate</b>	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	209-150-3
<b>Microcrystalline cellulose</b>	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex XVII - Restrictions on Certain Dangerous Substances:	Use restricted. See item 9[f]. powder
EU EINECS/ELINCS List	232-674-9
<b>Sodium Lauryl Sulfate</b>	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 6
EU EINECS/ELINCS List	205-788-1
<b>Sodium starch glycolate</b>	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

### 16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

## SAFETY DATA SHEET

**Material Name:** Doxazosin mesylate tablets  
**Revision date:** 16-Jun-2014

**Page 10 of 10**  
**Version: 4.1**

---

Specific target organ toxicity, repeated exposure-Cat.2; H373 - May cause damage to organs through prolonged or repeated exposure  
Hazardous to the aquatic environment, acute toxicity-Cat.2; H401 - Toxic to aquatic life  
Hazardous to the aquatic environment, chronic toxicity-Cat.2; H411 - Toxic to aquatic life with long lasting effects

Xn - Harmful

R48/22 - Harmful: danger of serious damage to health by prolonged exposure if swallowed.

**Data Sources:** Pfizer proprietary drug development information.

**Reasons for Revision:** Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 11 - Toxicology Information. Updated Section 16 - Other Information.

**Revision date:** 16-Jun-2014

**Prepared by:** Product Stewardship Hazard Communication  
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**End of Safety Data Sheet**